NGVT Ingevity Corp
Chemicals & Allied Products · NYSE · SEC CIK 1653477 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.7%
TTM net income YoY190.7%
TTM EPS YoY196.1%
Revenue 3-yr CAGR-12.7%
Net income 3-yr CAGR-22.2%
Margins
Gross margin42.0%
Operating margin—
Net margin5.3%
FCF margin10.8%
EBITDA margin—
Returns
ROE59.5%
ROA3.6%
ROIC (approx.)—
Asset turnover0.68x
Leverage & solvency
Liabilities / assets95.8%
Debt / equity18.18x
Current ratio1.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.02x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $305.10M | $314.10M | $258.00M | $255.10M | $333.10M | $331.50M | $247.90M | $263.30M |
| Cost of revenue | $172.30M | $175.10M | $141.60M | $167.30M | $199.20M | $203.70M | $136.00M | $163.40M |
| Gross profit | $132.80M | $139.00M | $116.40M | $87.80M | $133.90M | $127.80M | $111.90M | $99.90M |
| R&D expense | $8.30M | $6.10M | $6.70M | $7.40M | $7.00M | $7.00M | $7.00M | $6.50M |
| SG&A expense | $38.10M | $39.00M | $40.70M | $41.60M | $44.10M | $43.60M | $41.90M | $38.30M |
| Operating income | — | — | — | — | — | — | — | $80.60M |
| Pretax income | $68.90M | $50.70M | $30.20M | -$105.30M | $62.20M | -$136.60M | $37.60M | $24.10M |
| Income tax | $17.80M | $10.90M | $6.80M | -$26.60M | $21.40M | $4.80M | $8.50M | $4.50M |
| Net income | $49.30M | $35.30M | $59.80M | -$84.60M | $43.50M | -$146.50M | $20.50M | $16.60M |
| EBITDA | — | — | — | — | — | — | — | $105.80M |
| EPS (basic) | 1.44 | 1.02 | 1.70 | — | 1.20 | -4.02 | 0.56 | — |
| EPS (diluted) | 1.41 | 1.00 | 1.66 | — | 1.18 | -4.02 | 0.56 | — |
| Weighted avg. shares (diluted) | 34.85M | 35.28M | 36.02M | — | 36.95M | 36.46M | 36.66M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $85.40M | $97.40M | $95.40M | $78.10M | $83.40M | $76.90M | $71.50M | $68.00M |
| Inventory | $153.90M | $154.00M | $203.60M | $186.00M | $193.70M | $220.30M | $245.40M | $195.90M |
| Current assets | $531.70M | $543.80M | $581.80M | $454.20M | $522.20M | $536.00M | $530.00M | $493.20M |
| PP&E, net | $572.40M | $575.00M | $599.80M | $608.10M | $629.70M | $654.60M | $655.80M | $642.90M |
| Goodwill | $4.30M | $4.30M | $4.30M | $4.30M | $4.30M | $4.30M | $180.70M | $175.20M |
| Intangibles | $133.20M | $137.30M | $168.00M | $176.10M | $267.60M | $279.10M | $276.80M | $278.80M |
| Total assets | $1.50B | $1.54B | $1.65B | $1.65B | $1.83B | $1.88B | $2.06B | $2.02B |
| Current liabilities | $359.00M | $337.60M | $409.40M | $341.30M | $411.60M | $393.10M | $264.60M | $264.10M |
| Short-term debt | $156.40M | $144.00M | $121.90M | $47.10M | $102.00M | $94.70M | $60.40M | $61.30M |
| Long-term debt | $989.10M | $1.06B | $1.08B | $1.16B | $1.16B | $1.24B | $1.33B | $1.34B |
| Total debt | $1.15B | $1.20B | $1.20B | $1.21B | $1.26B | $1.33B | $1.39B | $1.40B |
| Total liabilities | $1.44B | $1.49B | $1.61B | $1.62B | $1.70B | $1.76B | $1.82B | $1.83B |
| Shareholders' equity | $63.00M | $46.90M | $38.90M | $29.70M | $138.10M | $120.70M | $234.60M | $195.20M |
| Net debt | $1.06B | $1.10B | $1.11B | $1.13B | $1.18B | $1.25B | $1.32B | $1.33B |
| Shares outstanding | 33.96M | 34.48M | 34.89M | 35.49M | 36.05M | 36.47M | 36.45M | 36.35M |
| Cash flow statement | ||||||||
| Operating cash flow | $99.20M | -$13.80M | -$2.00M | $97.10M | $129.70M | $79.00M | $25.40M | $64.50M |
| Capital expenditure | $13.70M | $10.30M | $10.30M | $23.60M | $11.90M | $12.20M | $10.00M | $24.90M |
| Free cash flow | $85.50M | -$24.10M | -$12.30M | $73.50M | $117.80M | $66.80M | $15.40M | $39.60M |
| Investing cash flow | -$11.20M | $75.40M | $106.30M | -$15.10M | -$28.10M | -$2.80M | -$11.50M | -$28.00M |
| Financing cash flow | -$93.70M | -$37.60M | -$61.80M | -$83.40M | -$94.80M | -$63.00M | -$11.00M | -$97.60M |
| Depreciation & amortization | $20.90M | $22.00M | $22.70M | $27.90M | $28.00M | $25.60M | $24.90M | $25.20M |
| Stock-based compensation | $4.00M | $4.20M | $4.80M | $4.50M | $5.30M | $4.40M | $4.10M | $2.10M |
| Share buybacks | $38.50M | $34.50M | $52.30M | $31.10M | $25.20M | $0 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.